Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy — ROSALIE  

Breast Cancer Clinical Trial

Official title: Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy

Status Not yet recruiting

Clinical Trial Summary

To de-escalate radiation therapy in women with breast cancer.

Clinical Trial Description

The study is a prospective, multi-center, single arm cohort study of omission of adjuvant whole breast radiation therapy (WBRT) following breast conserving surgery (BCS) in patients with a pathological complete response (pCR) following neoadjuvant chemotherapy (NAC). Eligible and consenting female patients with newly diagnosed T1-3 node negative breast cancer with no clinical evidence of distant metastatic disease, who have been treated with NAC, BCS and axillary staging surgery with final pathology demonstrating a pCR (ypT0N0) will be enrolled to the study and followed. The first analysis is planned when follow-up is a median of 5 years. Study participants will not receive adjuvant WBRT, the current standard of care. The primary outcome is ipsilateral breast tumour recurrence (IBTR) at median 5-year follow-up. Study participants will be followed and assessed for local recurrence, regional recurrence, distant recurrence, DFS and OS. In addition, any additional breast cancer treatments received by the participant for the first recurrence event including repeat BCS, mastectomy, additional systemic therapy and radiation therapy (RT) will be documented. The planned sample size is 352 study participants. ;

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

• NCT number: NCT05866458
• Study type: Observational
• Source: Ontario Clinical Oncology Group (OCOG)
• Contact: Adrianne Van Dam
• Phone: 905-527-2299
• Email: avandam@mcmaster.ca
• Status: Not yet recruiting
• Start date: September 2023
• Completion date: October 2031